// Imugene Announces Presentation on HER-Vaxx Cancer Vaccine at the American Association for Cancer Research 2019 Annual Meeting - Finance News Network Skip to main content

Despite Katie Couric’s Advice, Doctors Say Ultrasound Breast Exams May Not Be Needed

Image
usf health primary care :: Article Creator The VA Adds A Veterans Health Clinic In An East Tampa Neighborhood A new satellite clinic run by the Department of Veteran Affairs in East Tampa is open for veterans to get primary care, mental health support and other services. It's part of a growing partnership between the Department of Veterans Affairs and Department of Defense. Officials from both agencies celebrated the Sabal Park clinic's grand opening during a ceremony on Monday. In the last year, the VA reported nearly 33,000 veterans in Florida signed up for health care. Many of them live in the Tampa Bay region, which has one of the largest veteran populations in the U.S. "It is always a challenge to have capacity meet that ever-growing demand, but it is our obligation to catch up to that demand as much as possible," Dr. Shereef Elnahal, VA Under Secretary for Health, said at the event. Stephanie Colombini / WUS

Imugene Announces Presentation on HER-Vaxx Cancer Vaccine at the American Association for Cancer Research 2019 Annual Meeting - Finance News Network

Media ReleasesImugene Limited

SYDNEY, Australia, 28 February 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Professor Ursula Wiedermann will present on the HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

The poster (abstract number 8249) will be presented by Prof Wiedermann, the co-inventor of the HER-Vaxx cancer vaccine and member of the Company’s Scientific Advisory Board, at the AACR Annual Meeting in Atlanta, Georgia scheduled for March 29 to April 3, 2019.

The abstract presentation is entitled ‘A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach.’

For further information please download PDF attached: Download this document



https://ift.tt/2C6RYzt

Comments

Popular posts from this blog

Observership Program listings for international medical graduates

Vaccination Sites | Covid-19

Vaccination Sites | Covid-19